Exosome Diagnostics, Life Technologies Ink Agreement for Oncology Dx Program | GenomeWeb

NEW YORK (GenomeWeb News) – Exosome Diagnostics today said that it has signed an agreement with Life Technologies to use the Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument for its exosome biofluid in vitro diagnostics program.

Exosome will validate the 7500 platform with exosome biofluid RNA isolation kits in clinical trials beginning this year in brain and prostate cancer. Terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.